Cellectis, the gene-editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, today announced the achievement of a significant milestone under the Company's collaboration agreement with Servier, in the pre-clinical development of two next-generation product candidates in solid tumors. Under the terms of the Company's collaboration agreement with Servier, Cellectis is eligible to an undisclosed payment.
The collaboration announced in February 2014, is focused on research, development, and potentially commercialization of six product candidates targeting leukemia and solid tumors.
“We are very pleased with the productiviy of this alliance enabling us to accelerate our development in the field of solid tumors”, commented Mathieu Simon, MD, EVP Chief Operating Officer of Cellectis.
“We believe that immunotherapy will dramatically change the management of metastatic cancers. Our goal at Servier is to make these new technologies available for the largest number of cancer patients”, commented by Jean-Pierre Abastado, MD, Director Oncology Innovation Therapeutic Pole of Servier.
